Cognitive performance and response inhibition in developmentally vitamin D (DVD)-deficient rats

Behavioural Brain Research

Volumn 242, Issue 1, 2013, Pages 47-53

  Turner, Karly M ^a   Young, Jared W ^b   McGrath, John J ^a,c   Eyles, Darryl W ^a,c   Burne, Thomas H J ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c QUEENSLAND CENTRE FOR MENTAL HEALTH RESEARCH   (Australia)

Author keywords

Animal model; Attention; Clozapine; Rat; Schizophrenia; Vitamin D

Indexed keywords

CLOZAPINE; VITAMIN D;

5 CHOICE CONTINUOUS PERFORMANCE TEST; 5 CHOICE SERIAL REACTION TIME TASK; ACCURACY; ALERTNESS; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; ATTITUDE; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DEVELOPMENTAL VITAMIN D DEFICIENCY; DISEASE ACTIVITY; EXPERIMENTAL MODEL; FEMALE; IMPULSIVENESS; INHIBITION (PSYCHOLOGY); LATENT PERIOD; MALE; MENTAL PERFORMANCE; NONHUMAN; PERCEPTIVE DISCRIMINATION; PERSEVERATION; PRIORITY JOURNAL; PROGENY; PSYCHOLOGIC ASSESSMENT; RAT; REACTION TIME; REWARD; SCHIZOPHRENIA; TASK PERFORMANCE; TREATMENT RESPONSE; VITAMIN D DEFICIENCY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; CLOZAPINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; INHIBITION (PSYCHOLOGY); MALE; PROBABILITY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VITAMIN D DEFICIENCY;

EID: 84872242501     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.029     Document Type: Article

References (45)

1. McGrath J.J., Susser E.S. New directions in the epidemiology of schizophrenia. Medical Journal of Australia 2009, 190:S7-S9.
2. Goff D.C., Hill M., Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacology Biochemistry and Behavior 2011, 99:245-253.
3. Welham J., Isohanni M., Jones P., McGrath J. The antecedents of schizophrenia: a review of birth cohort studies. Schizophr Bulletin 2009, 35:603-623.
4. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry 1991, 48:239-246.
5. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff" ?. Schizophrenia Bulletin 2000, 26:119-136.
6. McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia?. Schizophrenia Research 1999, 40:173-177.
7. Torrey E.F., Miller J., Rawlings R., Yolken R.H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophrenia Research 1997, 28:1-38.
8. Davies G., Welham J., Chant D., Torrey E.F., McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophrenia Bulletin 2003, 29:587-593.
9. Saha S., Chant D.C., Welham J.L., McGrath J.J. The incidence and prevalence of schizophrenia varies with latitude. Acta Psychiatrica Scandinavica 2006, 114:36-39.
10. McGrath J.J., Eyles D.W., Pedersen C.B., Anderson C., Ko P., Burne T.H., et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Archives of General Psychiatry 2010, 67:889-894.
11. Harms L.R., Burne T.H., Eyles D.W., McGrath J.J. Vitamin D and the brain. Best Practice in Research on Clinical Endocrinology and Metabolism 2011, 25:657-669.
12. McGrath J.J., Burne T.H., Feron F., Mackay-Sim A., Eyles D.W. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophrenia Bulletin 2010, 36:1073-1078.
13. Brown J., Bianco J.I., McGrath J.J., Eyles D.W. 1,25-Dihydroxyvitamin D(3) induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neuroscience Letters 2003, 343:139-143.
14. Cui X., Pelekanos M., Burne T.H., McGrath J.J., Eyles D.W. Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. Neuroscience Letters 2010, 486:220-223.
15. Kesby J.P., Cui X., Ko P., McGrath J.J., Burne T.H., Eyles D.W. Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. Neuroscience Letters 2009, 461:155-158.
16. Feron F., Burne T.H., Brown J., Smith E., McGrath J.J., Mackay-Sim A., et al. Developmental Vitamin D(3) deficiency alters the adult rat brain. Brain Research Bulletin 2005, 65:141-148.
17. Almeras L., Eyles D., Benech P., Laffite D., Villard C., Patatian A., et al. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics 2007, 7:769-780.
18. Burne T.H., Becker A., Brown J., Eyles D.W., Mackay-Sim A., McGrath J.J. Transient prenatal Vitamin D deficiency is associated with hyperlocomotion in adult rats. Behavioural Brain Research 2004, 154:549-555.
19. Burne T.H., O'Loan J., McGrath J.J., Eyles D.W. Hyperlocomotion associated with transient prenatal vitamin D deficiency is ameliorated by acute restraint. Behavioural Brain Research 2006, 174:119-124.
20. Kesby J.P., Burne T.H., McGrath J.J., Eyles D.W. Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia. Biological Psychiatry 2006, 60:591-596.
21. Becker A., Eyles D.W., McGrath J.J., Grecksch G. Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. Behavioural Brain Research 2005, 161:306-312.
22. Kesby J.P., O'Loan J.C., Alexander S., Deng C., Huang X.F., McGrath J.J., et al. Developmental vitamin D deficiency alters MK-801-induced behaviours in adult offspring. Psychopharmacology 2012, 220:455-463.
23. Young J.W., Powell S.B., Risbrough V., Marston H.M., Geyer M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacology and Therapeutics 2009, 122:150-202.
24. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 2002, 163:362-380.
25. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. The American Journal of Psychiatry 2008, 165:203-213.
26. Young J.W., Light G.A., Marston H.M., Sharp R., Geyer M.A. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS ONE 2009, 4:e4227.
27. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Critical Reviews in Neurobiology 2000, 14:1-21.
28. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin 2005, 31:5-19.
29. Robbins T.W. Synthesizing schizophrenia: a bottom-up, symptomatic approach. Schizophrenia Bulletin 2005, 31:854-864.
30. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry 2004, 55:1013-1022.
31. Amitai N., Semenova S., Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) 2007, 193:521-537.
32. Eyles D., Burne T.H., Alexander S., Cui X., Mcgrath J.J. The developmental vitamin D (DVD) model of schizophrenia. Animal Models of Schizophrenia and Related Disorders 2011, 113-125. Humana Press, Totowa, NJ. P. O'Donnell (Ed.).
33. Bari A., Dalley J.W., Robbins T.W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nature protocols 2008, 3:759-767.
34. Paine T.A., Carlezon W.A. Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats. Neuropharmacology 2009, 56:788-797.
35. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. European Journal of Pharmacology 1995, 281:241-250.
36. Baviera M., Invernizzi R.W., Carli M. Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. Psychopharmacology (Berl) 2008, 196:269-280.
37. Barnes S.A., Young J.W., Neill J.C. Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased. Neuropharmacology 2012, 62:1432-1441.
38. Jenkins T.A., Harte M.K., McKibben C.E., Elliott J.J., Reynolds G.P. Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behavioural Brain Research 2008, 194:230-235.
39. McLean S.L., Beck J.P., Woolley M.L., Neill J.C. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behavioural Brain Research 2008, 189:152-158.
40. Wiley J.L., Compton A.D. Progressive ratio performance following challenge with antipsychotics, amphetamine, or NMDA antagonists in adult rats treated perinatally with phencyclidine. Psychopharmacology 2004, 177:170-177.
41. Sams-Dodd F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology (Berl) 1998, 135:182-193.
42. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Molecular Psychiatry 2002, 7:837-844.
43. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999, 25:233-255.
44. Gardner D.M., Baldessarini R.J., Waraich P. Modern antipsychotic drugs: a critical overview. Canadian Medical Association Journal 2005, 172:1703-1711.
45. Carli M., Baviera M., Invernizzi R.W., Balducci C. Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 2006, 31:757-767.